Analyst Price Targets — OPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 25, 2025 12:20 pm | Matthew Caufield | H.C. Wainwright | $2.00 | $3.41 | TheFly | Opthea downgraded to Neutral from Buy at H.C. Wainwright |
| December 8, 2022 6:19 am | — | H.C. Wainwright | $14.00 | $4.97 | Benzinga | HC Wainwright & Co. Initiates Coverage On Opthea with Buy Rating, Announces Price Target of $14 |
Latest News for OPT
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPT.
U.S. House Trading
No House trades found for OPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.